Mounjaro on NHS England: the rollout, the criteria, and what it means for you

What the NICE guidance actually says, and why the NHS rollout is phased

NICE published its appraisal of tirzepatide for weight management in December 2024 and updated it in September 2025, recommending the medicine for adults with a BMI of 35 or above alongside at least one weight-related comorbidity. You can read the full NICE technology appraisal TA1026 on the NICE website. The qualifying conditions the guidance specifies are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

NHS England chose a phased implementation rather than opening access all at once, partly because of supply constraints and partly to give GP practices time to build the wraparound diet and activity support that the guidance requires. That phasing means the criteria for NHS prescribing are, for now, stricter than the NICE recommendation itself.

Under-18s are not licensed for this treatment, and lower BMI thresholds apply for adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the adjustment is 2.5 kg/m² throughout the rollout. So a threshold of 40 effectively becomes 37.5 for those groups.

One thing worth noting: even if you meet every number on paper, your GP practice needs to have opted into the scheme. Participation is optional under the 2026/27 GP contract, so provision varies considerably by area. The NHS England tirzepatide rollout page on this site covers the GP-contract detail in more depth.

The three cohorts opening between 2025 and 2027

The phased structure breaks into three distinct groups. The first cohort, which opened in June 2025, requires a BMI of 40 or above plus four or more of the five qualifying conditions listed above. That is a deliberately narrow group, people with the highest clinical need.

Cohort 2 activated on 23 June 2026, extending access to adults with a BMI between 35 and 39.9 who also have four or more of those conditions. If you are in this band and have multiple conditions, it is worth speaking to your GP now, since some practices will have capacity and others will not.

From around March 2027, the criteria are expected to widen again to include people with a BMI of 40 or above and three (rather than four) of the five conditions. Subsequent cohorts will eventually reach the full NICE-recommended population, though the timeline for that remains subject to commissioning decisions.

All of this assumes continuous NHS funding and supply. It is also worth bearing in mind that NHS Mounjaro prescribing comes with a requirement to engage with structured lifestyle support, it is not just a prescription in isolation. If you want a broader view of how NHS and private routes compare, the Mounjaro on the NHS overview covers both sides plainly.

What happens when the criteria are not met, or the wait is too long

This is the question most people searching for Mounjaro on NHS England are really asking. If your BMI sits at 34 with two conditions, or 38 with three, you do not qualify under current NHS rules regardless of how significant your health impact is. Many people are in that position, and it is genuinely frustrating.

Private prescribing through a regulated UK online pharmacy is the alternative. The licensed private eligibility criteria are set by the medicine's licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. That is considerably broader than the NHS route. A prescriber still assesses every case individually (a BMI alone is never the whole picture) but the population who can access treatment privately is much larger than the NHS cohort.

If cost is the consideration keeping you on the NHS waiting list, the Mounjaro price comparison page is worth reading before making any assumptions. Private prices have changed significantly since Eli Lilly revised its UK list price in September 2025, and what different providers actually include in their quoted price varies widely.

Scotland operates differently, thresholds and access routes diverge from England's. The Mounjaro on the NHS in Scotland page explains the Scottish picture separately.

How a private prescription works if NHS England criteria are not met yet

Getting a private prescription for tirzepatide starts with a clinical consultation, not a checkout page. A GPhC-registered Independent Prescriber reviews your medical history, weight, any relevant conditions and medications, a real clinician, the same day you submit your answers, not a queued automated check. Identity and weight are verified directly.

If you are clinically suitable, treatment can be dispatched the same day for orders placed before noon on a weekday, arriving the next working day by tracked DPD delivery in plain packaging. There are no subscriptions: each repeat order goes through clinical review again before anything is sent.

One practical note on timing: if you are planning to start before a holiday or over a bank holiday weekend, factor in that same-day dispatch applies to working days only. Ordering on a Thursday before a long weekend means Tuesday delivery, not Friday.

If you want to understand what Mounjaro actually is before deciding anything, the Mounjaro overview covers the mechanism, evidence and what treatment involves, including what the NHS says about Mounjaro and hair loss as a side effect worth knowing about before you start. For questions about what private treatment through a registered pharmacy looks like in practice, about our service has the detail. When you are ready, check your eligibility with our prescribers, it is free and there is no obligation.